Summary
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative medicines for diseases with unmet medical need. The company offers products in various therapeutic areas including cardiovascular, respiratory, inflammation, liver diseases and cancer. It develops pharmaceutical products for HIV. Gilead operates in the US and across the world with more than 40 marketing subsidiaries in the Czech Republic, Denmark, Finland, France, Australia, Austria, Belgium and Canada, among others. It operates in Europe, North America and South America and Asia-Pacific. The company continues to add to its existing portfolio of products through its internal discovery and clinical development programs and through a product acquisition and in-licensing strategy. Gilead is headquartered in Foster City, California, the US.
Gilead Sciences, Inc. (GILD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 8
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 9
Gilead Sciences, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 10
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 11
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 12
Gilead Sciences, Inc., Medical Devices Deals, 2010 to YTD 2016 14
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 15
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deal Details 22
Asset Purchase 22
Gilead Sciences to Acquire Farnesoid X Receptor Program from Phenex Pharma 22
Gilead Sciences Completes Acquisition Of Oceanside Clinical Plant From Genentech For US$28.3 Million 24
Venture Financing 25
EpiTherapeutics Secures An Additional US$1.69 Million In Seed Financing 25
EpiTherapeutics Secures An Additional US$1.37 Million In Seed Financing 27
Calistoga Pharma Secures US$40 Million In Series C Financing 29
EpiTherapeutics Raises Additional US$2 Million In Seed Financing Round 31
Partnerships 32
Janssen Amends Licensing Agreement with Gilead for STR 32
Gilead Sciences Enters into Co-Development Agreement with Galapagos 33
Spring Bank Pharma Enters into Agreement with Gilead Sciences 34
X-Rx Enters into Agreement with Gilead Sciences 35
Gilead Sciences Partners with WuXi PharmaTech 36
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 37
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 38
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 40
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 42
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 43
Adimab Enters Into Co-Development Agreement With Gilead Sciences 44
CanAm Bioresearch Enters Into An Agreement With EpiTherapeutics 45
Gilead Sciences Enters Into Research Collaboration With Yale School of Medicine 46
EpiTherapeutics Enters Into Co-Development Agreement With Abbott 48
Selcia Enters Into Collaboration With Gilead Sciences 49
Nuevolution Enters Into Discovery Collaboration With EpiTherapeutics, ExpreS2ion And University of Copenhagen 50
Merger 51
Cytopia Merges With YM BioSciences 51
Licensing Agreements 53
Medicines Patent Pool Expands Licensing Agreement with Gilead Sciences 53
Natco Pharma Enters into Licensing Agreement with Gilead Sciences 54
Gilead Sciences Expands Licensing Agreement with Mylan Labs 55
Biocon Enters into Licensing Agreement with Gilead Sciences 56
Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 57
Janssen Expands Licensing Agreement with Gilead 58
Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 59
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 60
Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 61
Gilead Sciences Enters into Licensing Agreement with Cipla 62
Gilead Sciences Enters into Licensing Agreement with Hetero Labs 63
Gilead Sciences Enters into Licensing Agreement with Mylan Labs 64
Gilead Sciences Enters into Licensing Agreement with Ranbaxy Labs 65
Gilead Sciences Enters into Licensing Agreement with SeQuent Scientific 66
Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 67
Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences 69
Parion Sciences Enters Into Licensing Agreement With Gilead Sciences 70
Gilead Sciences Enters Into Licensing Agreement With CURx Pharma 71
Gilead Sciences Plans To License Hepatitis C Drug, Sovaldi 72
Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 73
Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences 75
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 76
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 78
Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 80
Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 81
Achillion Pharma Terminates Licensing Agreement With Gilead Sciences 83
Japan Tobacco Enters Into Licensing Agreement With Gilead Sciences For cobicistat 84
AvidBiologics Enters into Agreement With YM BioSciences, NRC-BRI and Fox Chase Cancer Centre 85
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 86
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences 87
Gilead Sciences Enters Into Licensing Agreement With GlobeImmune 89
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 91
Gilead Sciences Extends Licensing Agreement With Hetero Drugs For Tenofovir, Elvitegravir, Cobicistat And Quad 93
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 95
Gilead Sciences Extends Licensing Agreement With Ranbaxy Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 97
Gilead Sciences Extends Licensing Agreement With Strides Arcolab For Tenofovir, Elvitegravir, Cobicistat And Quad 99
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 101
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637 102
Yuhan Enters Into Licensing Agreement With Gilead Sciences For Viread 103
VetDC Enters Into Licensing Agreement With Gilead Sciences For GS 9219 104
Equity Offering 105
Galapagos Raises USD425 Million in Private Placement of Shares 105
YM BioSciences Completes Public Offering Of Common Stock For US$80 Million 107
YM BioSciences Completes Underwritten Public Offering Of US$46 Million 109
YM BioSciences Completes Private Placement Of US$3.2 Million 111
YM BioSciences Completes Registered Direct Offering Of Units For US$17.5 Million 113
Debt Offering 115
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 115
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 117
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 119
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 121
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 123
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 125
Gilead Sciences Raises USD500 Million in Public Offering of 2.35% Notes Due 2020 127
Gilead Sciences Raises USD1.8 Billion in Public Offering of 3.5% Notes Due 2025 129
Gilead Sciences Raises USD1.8 Billion in Public Offering of 4.5% Notes Due 2045 131
Gilead Sciences Completes Public Offering Of Notes Due 2019 For US$500 Million 133
Gilead Sciences Completes Public Offering Of Notes Due 2024 For US$1.75 Billion 135
Gilead Sciences Completes Public Offering Of Notes Due 2044 For US$1.75 Billion 137
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million 139
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$700 Million 141
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1.25 Billion 143
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$1 Billion 145
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1,000 Million 147
Gilead Sciences Completes Private Placement Of 1% Senior Notes For US$1,100 Million 149
Gilead Sciences Completes Private Placement Of 1.625% Senior Notes For US$1,100 Million 151
Asset Transactions 153
Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 153
Acquisition 154
Gilead Sciences to Acquire Nimbus Apollo from Nimbus Therapeutics 154
Gilead Sciences Acquires EpiTherapeutics for USD65 Million 156
Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company 158
Gilead Sciences Completes Acquisition Of Pharmasset For US$11.2 Billion 161
Gilead Sciences Acquires Calistoga Pharma 164
Gilead Sciences Acquires Arresto Biosciences 166
Gilead Sciences Acquires CGI Pharma 168
Gilead Sciences, Inc. - Key Competitors 171
Key Employees 172
Locations And Subsidiaries 174
Head Office 174
Other Locations & Subsidiaries 174
Appendix 179
Methodology 179
About GlobalData 179
Contact Us 179
Disclaimer 179
List of Tables
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 9
Gilead Sciences, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 10
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 11
Gilead Sciences, Inc., Deals By Therapy Area, 2010 to YTD 2016 12
Gilead Sciences, Inc., Medical Devices Deals, 2010 to YTD 2016 14
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 15
Gilead Sciences to Acquire Farnesoid X Receptor Program from Phenex Pharma 22
Gilead Sciences Completes Acquisition Of Oceanside Clinical Plant From Genentech For US$28.3 Million 24
EpiTherapeutics Secures An Additional US$1.69 Million In Seed Financing 25
EpiTherapeutics Secures An Additional US$1.37 Million In Seed Financing 27
Calistoga Pharma Secures US$40 Million In Series C Financing 29
EpiTherapeutics Raises Additional US$2 Million In Seed Financing Round 31
Janssen Amends Licensing Agreement with Gilead for STR 32
Gilead Sciences Enters into Co-Development Agreement with Galapagos 33
Spring Bank Pharma Enters into Agreement with Gilead Sciences 34
X-Rx Enters into Agreement with Gilead Sciences 35
Gilead Sciences Partners with WuXi PharmaTech 36
Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 37
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 38
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 40
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 42
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 43
Adimab Enters Into Co-Development Agreement With Gilead Sciences 44
CanAm Bioresearch Enters Into An Agreement With EpiTherapeutics 45
Gilead Sciences Enters Into Research Collaboration With Yale School of Medicine 46
EpiTherapeutics Enters Into Co-Development Agreement With Abbott 48
Selcia Enters Into Collaboration With Gilead Sciences 49
Nuevolution Enters Into Discovery Collaboration With EpiTherapeutics, ExpreS2ion And University of Copenhagen 50
Cytopia Merges With YM BioSciences 51
Medicines Patent Pool Expands Licensing Agreement with Gilead Sciences 53
Natco Pharma Enters into Licensing Agreement with Gilead Sciences 54
Gilead Sciences Expands Licensing Agreement with Mylan Labs 55
Biocon Enters into Licensing Agreement with Gilead Sciences 56
Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 57
Janssen Expands Licensing Agreement with Gilead 58
Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 59
Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 60
Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 61
Gilead Sciences Enters into Licensing Agreement with Cipla 62
Gilead Sciences Enters into Licensing Agreement with Hetero Labs 63
Gilead Sciences Enters into Licensing Agreement with Mylan Labs 64
Gilead Sciences Enters into Licensing Agreement with Ranbaxy Labs 65
Gilead Sciences Enters into Licensing Agreement with SeQuent Scientific 66
Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 67
Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences 69
Parion Sciences Enters Into Licensing Agreement With Gilead Sciences 70
Gilead Sciences Enters Into Licensing Agreement With CURx Pharma 71
Gilead Sciences Plans To License Hepatitis C Drug, Sovaldi 72
Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 73
Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences 75
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 76
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 78
Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 80
Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 81
Achillion Pharma Terminates Licensing Agreement With Gilead Sciences 83
Japan Tobacco Enters Into Licensing Agreement With Gilead Sciences For cobicistat 84
AvidBiologics Enters into Agreement With YM BioSciences, NRC-BRI and Fox Chase Cancer Centre 85
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 86
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences 87
Gilead Sciences Enters Into Licensing Agreement With GlobeImmune 89
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 91
Gilead Sciences Extends Licensing Agreement With Hetero Drugs For Tenofovir, Elvitegravir, Cobicistat And Quad 93
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 95
Gilead Sciences Extends Licensing Agreement With Ranbaxy Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 97
Gilead Sciences Extends Licensing Agreement With Strides Arcolab For Tenofovir, Elvitegravir, Cobicistat And Quad 99
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 101
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637 102
Yuhan Enters Into Licensing Agreement With Gilead Sciences For Viread 103
VetDC Enters Into Licensing Agreement With Gilead Sciences For GS 9219 104
Galapagos Raises USD425 Million in Private Placement of Shares 105
YM BioSciences Completes Public Offering Of Common Stock For US$80 Million 107
YM BioSciences Completes Underwritten Public Offering Of US$46 Million 109
YM BioSciences Completes Private Placement Of US$3.2 Million 111
YM BioSciences Completes Registered Direct Offering Of Units For US$17.5 Million 113
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 115
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 117
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 119
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 121
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 123
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 125
Gilead Sciences Raises USD500 Million in Public Offering of 2.35% Notes Due 2020 127
Gilead Sciences Raises USD1.8 Billion in Public Offering of 3.5% Notes Due 2025 129
Gilead Sciences Raises USD1.8 Billion in Public Offering of 4.5% Notes Due 2045 131
Gilead Sciences Completes Public Offering Of Notes Due 2019 For US$500 Million 133
Gilead Sciences Completes Public Offering Of Notes Due 2024 For US$1.75 Billion 135
Gilead Sciences Completes Public Offering Of Notes Due 2044 For US$1.75 Billion 137
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million 139
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$700 Million 141
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1.25 Billion 143
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$1 Billion 145
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1,000 Million 147
Gilead Sciences Completes Private Placement Of 1% Senior Notes For US$1,100 Million 149
Gilead Sciences Completes Private Placement Of 1.625% Senior Notes For US$1,100 Million 151
Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 153
Gilead Sciences to Acquire Nimbus Apollo from Nimbus Therapeutics 154
Gilead Sciences Acquires EpiTherapeutics for USD65 Million 156
Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company 158
Gilead Sciences Completes Acquisition Of Pharmasset For US$11.2 Billion 161
Gilead Sciences Acquires Calistoga Pharma 164
Gilead Sciences Acquires Arresto Biosciences 166
Gilead Sciences Acquires CGI Pharma 168
Gilead Sciences, Inc., Key Competitors 171
Gilead Sciences, Inc., Key Employees 172
Gilead Sciences, Inc., Other Locations 174
Gilead Sciences, Inc., Subsidiaries 175
List of Figures
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 9
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 10
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 11
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 12
Gilead Sciences, Inc., Medical Devices Deals, 2010 to YTD 2016 14
